MY133503A - Selective iglur5 receptor antagonists for the treatment of migrane - Google Patents

Selective iglur5 receptor antagonists for the treatment of migrane

Info

Publication number
MY133503A
MY133503A MYPI20003046A MY133503A MY 133503 A MY133503 A MY 133503A MY PI20003046 A MYPI20003046 A MY PI20003046A MY 133503 A MY133503 A MY 133503A
Authority
MY
Malaysia
Prior art keywords
iglur5 receptor
migrane
treatment
selective iglur5
receptor antagonists
Prior art date
Application number
Other languages
English (en)
Inventor
Ann Filla Sandra
Bleakman David
Suzon Chappell Amy
Willis Johnson Kirk
Leslie Ornstein Paul
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY133503A publication Critical patent/MY133503A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI20003046 1999-07-06 2000-07-04 Selective iglur5 receptor antagonists for the treatment of migrane MY133503A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US15116599P 1999-08-27 1999-08-27

Publications (1)

Publication Number Publication Date
MY133503A true MY133503A (en) 2007-11-30

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20003046 MY133503A (en) 1999-07-06 2000-07-04 Selective iglur5 receptor antagonists for the treatment of migrane

Country Status (28)

Country Link
US (4) US6566370B1 (enExample)
EP (1) EP1200073B1 (enExample)
JP (1) JP4619595B2 (enExample)
KR (1) KR20020024300A (enExample)
CN (1) CN1230174C (enExample)
AR (1) AR029373A1 (enExample)
AU (1) AU773304B2 (enExample)
BR (1) BR0012175A (enExample)
CA (1) CA2378613C (enExample)
CZ (1) CZ20014488A3 (enExample)
DE (1) DE60032905T2 (enExample)
DK (1) DK1200073T3 (enExample)
DZ (1) DZ3209A1 (enExample)
EA (1) EA004290B1 (enExample)
ES (1) ES2278619T3 (enExample)
HK (1) HK1047036A1 (enExample)
HR (1) HRP20020013A2 (enExample)
HU (1) HUP0202253A3 (enExample)
IL (1) IL146697A0 (enExample)
MX (1) MXPA01012726A (enExample)
MY (1) MY133503A (enExample)
NO (1) NO20016246L (enExample)
NZ (1) NZ515616A (enExample)
PE (1) PE20010299A1 (enExample)
PT (1) PT1200073E (enExample)
SK (1) SK112002A3 (enExample)
TR (1) TR200200066T2 (enExample)
WO (1) WO2001001972A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257545A1 (en) * 1999-12-22 2002-11-20 Eli Lilly And Company SELECTIVE iGLUR 5? RECEPTOR ANTAGONISTS
AU2002227020A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
MXPA03005981A (es) * 2001-01-05 2003-09-10 Lilly Co Eli Antagonistas de receptores de aminoacidos excitatorios.
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
DK1368032T3 (da) * 2001-01-05 2008-09-29 Lilly Co Eli Exitatoriske aminosyrereceptorantagonister
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6855725B2 (en) * 2001-01-05 2005-02-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
BR0308911A (pt) 2002-04-26 2005-01-04 Lilly Co Eli Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
MX2009002002A (es) 2006-08-23 2009-07-22 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8030518B2 (en) 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
JP7399096B2 (ja) 2018-03-05 2023-12-15 ヤンセン ファーマシューティカ エヌ．ベー． 神経変性を検出するためのアッセイ
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
MA56607A1 (fr) 2019-11-08 2022-10-31 Xenon Pharmaceuticals Inc Méthodes de traitement de troubles dépressifs
JP2024508660A (ja) 2021-02-09 2024-02-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
KR20010006075A (ko) 1997-04-07 2001-01-15 피터 지. 스트링거 약제
US6486175B1 (en) * 1999-07-06 2002-11-26 Eli Lilly And Company Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid

Also Published As

Publication number Publication date
EA004290B1 (ru) 2004-02-26
PT1200073E (pt) 2007-03-30
HK1047036A1 (zh) 2003-02-07
EA200200132A1 (ru) 2002-06-27
MXPA01012726A (es) 2002-07-02
DE60032905T2 (de) 2007-10-18
CN1359289A (zh) 2002-07-17
JP2003503449A (ja) 2003-01-28
KR20020024300A (ko) 2002-03-29
US6566370B1 (en) 2003-05-20
CA2378613C (en) 2007-10-02
CZ20014488A3 (cs) 2003-01-15
NO20016246L (no) 2002-03-04
ES2278619T3 (es) 2007-08-16
US20050159445A1 (en) 2005-07-21
US20030199546A1 (en) 2003-10-23
US20040192722A1 (en) 2004-09-30
WO2001001972A3 (en) 2001-12-06
BR0012175A (pt) 2002-03-05
US6855823B2 (en) 2005-02-15
PE20010299A1 (es) 2001-03-07
US7157582B2 (en) 2007-01-02
AU5873200A (en) 2001-01-22
DK1200073T3 (da) 2007-05-07
DZ3209A1 (fr) 2001-01-11
CA2378613A1 (en) 2001-01-11
EP1200073B1 (en) 2007-01-10
SK112002A3 (en) 2003-05-02
HUP0202253A3 (en) 2003-12-29
HRP20020013A2 (en) 2003-08-31
TR200200066T2 (tr) 2002-04-22
IL146697A0 (en) 2002-07-25
EP1200073A2 (en) 2002-05-02
JP4619595B2 (ja) 2011-01-26
US6759418B2 (en) 2004-07-06
AR029373A1 (es) 2003-06-25
NO20016246D0 (no) 2001-12-19
AU773304B2 (en) 2004-05-20
CN1230174C (zh) 2005-12-07
HUP0202253A2 (hu) 2002-11-28
NZ515616A (en) 2004-05-28
WO2001001972A2 (en) 2001-01-11
DE60032905D1 (de) 2007-02-22

Similar Documents

Publication Publication Date Title
MY133503A (en) Selective iglur5 receptor antagonists for the treatment of migrane
AU2003301020A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
MY116002A (en) Nk-1 receptor antagonists and 5ht3 receptor antagonists for the treatment of emesis
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
JO2371B1 (en) 4-phenyl-pyridine derivatives
MXPA03000548A (es) Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
SI1664016T1 (sl) Terapevtska sredstva, uporabna za zdravljenje bolečine
ATE342253T1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
IL162515A (en) Substituted diketopiperazines as oxytocin antagonists
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
MXPA02012574A (es) Uso novedoso de los antagonistas ii de angiotensina.
YU60803A (sh) Upotreba antagonista gal3 receptora u lečenju depresije i/ili uznemirenosti i jedinjenja korisna u tim postupcima
GB0019008D0 (en) Therapeutic compounds
GB0311349D0 (en) Therapeutic agents, compositions, preparations and uses
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine
ECSP003564A (es) ANTAGONISTAS SELECTIVOS DEL RECEPTOR DE iG1uR5 PARA EL TRATAMIENTO DE LA MIGRAÑA